<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/375C39D9-88B9-40AF-B8E8-A7261E1A12C8"><gtr:id>375C39D9-88B9-40AF-B8E8-A7261E1A12C8</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Stone</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500477"><gtr:id>68FACF1A-61E5-469C-86B1-36E0CEE71C6D</gtr:id><gtr:title>Investigating the role of brain glutamate in the aetiology of psychosis using magnetic resonance spectroscopy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0500477</gtr:grantReference><gtr:abstractText>In recent years there has been a move to try to reduce the severity of schizophrenia by treating it as early as possible. Many centres have started to try to treat individuals when they are exhibiting ?prodromal? symptoms, which are thought to precede the development of full psychotic symptoms. This carries some risk because only a proportion of these individuals will go on to develop schizophrenia, so those that do not may be treated unnecessarily. 
 I plan to study individuals with prodromal symptoms in order to determine whether they show similar neurochemical abnormalities as measured using magnetic resonance spectroscopy (a non-invasive technique to determine brain chemistry in living humans) to people with schizophrenia. I will also examine the effect of antipsychotic drugs on these changes, and try to identify particular characteristics from the MRS measurements that might distinguish those at risk of developing full psychotic symptoms. This study will help to understand the pathology underlying schizophrenia and has the potential for driving the development of new treatments for the condition. In addition, it may provide a quantitative method for assessing and diagnosing schizophrenia.</gtr:abstractText><gtr:technicalSummary>Untreated first episode schizophrenic patients and individuals at increased genetic risk for schizophrenia have elevated brain glutamate/glutamine as measured by magnetic resonance spectroscopy (MRS). This abnormality is reversed in chronic, treated schizophrenic patients. It has been hypothesised that elevated glutamate in the early stages of the illness may underlie the pathology that later develops, through excitotoxic cell death. Prevention or minimization of the harm putatively associated with elevated brain glutamate would be a prime target for intervention in schizophrenia. MRS has the potential to be a useful investigational tool to study glutamate/glutamine in vivo. 
 I propose to use MRS to examine brain glutamate in people who are at high risk of psychosis due to prodromal symptoms. 30 prodromal subjects will be scanned before and 6 weeks after the initiation of treatment with antipsychotic medication then followed clinically for 12 months. A group of 25 controls will also be scanned. Glutamate will be measured in the anterior cingulate and medial temporal cortex using a 3T MRI camera. Prodromal and psychotic symptoms will be assessed using the CAARMS. I will test the hypotheses that individuals with prodromal symptoms, who are at high risk of psychosis, have elevated levels of brain glutamate/glutamine demonstrable using MRS, that these normalise following antipsychotic treatment, and that persistently elevated glutamate is a predictor of subsequent transition to psychosis.
 In this study I will be collaborating with physicists in the Institute of Psychiatry and The Institute of Neurology. This study is timely and important since it allows, for the first time, estimation of the level of brain glutamate in individuals at high risk of developing schizophrenia. It will provide further information on the potential involvement of glutamate in the development of schizophrenia which could not be obtained by other means. The study also aims to identify aspects of the MRS scan which can predict progression from prodromal symptoms to frank psychosis. This has the potential to be developed into a useful clinical tool, which could minimise the morbidity associated with psychotic illness through enabling early or prophylactic treatment. Lastly, information from this study could help to develop better drug treatments for psychosis.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>224331</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School Presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C6FB7F87-D55B-4368-AE9D-C07C6409B871</gtr:id><gtr:impact>October 2011: &amp;quot;Science and the Brain&amp;quot; (Assembly for Science Week) - Brookfield Primary School, Camden London

Increase in interest in science - particularly neuroscience from pupils</gtr:impact><gtr:outcomeId>DBArAnibgzX</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Royal College of Psychiatrists Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4B325296-B815-4557-8A80-FA01586A0788</gtr:id><gtr:impact>Lecture to psychiatrists from Royal College at annual meeting.

Increase in awareness of research amongst clinicians.</gtr:impact><gtr:outcomeId>AF0A65D915D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oral presentation at 6th International Conference on Early Psychosis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C31815DA-BE49-408F-91EE-C04A9A4DA16C</gtr:id><gtr:impact>20 minutes lecture in Melbourne, Australia to scientists and psychiatrists with an interest in the at risk mental state and prodrome of psychosis.

Increased interest in research work from others in the field</gtr:impact><gtr:outcomeId>2CCB1F240EB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BRC Pump Priming</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>161C7FA1-15D5-4460-9572-6A12D9A6C61A</gtr:id><gtr:outcomeId>AB3C38853CC0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A6FFF57A-AC6F-4F9F-BF57-B11B41F78E59</gtr:id><gtr:title>Novel targets for drugs in schizophrenia.</gtr:title><gtr:parentPublicationTitle>CNS &amp; neurological disorders drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b1a2224b337a1dda5d402fdfa5fb51"><gtr:id>49b1a2224b337a1dda5d402fdfa5fb51</gtr:id><gtr:otherNames>Stone JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1871-5273</gtr:issn><gtr:outcomeId>673CFA87F0B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0F920F0-5860-4302-81DD-313ABACC145E</gtr:id><gtr:title>Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f919d9d0877818a50c27b63a222b581"><gtr:id>8f919d9d0877818a50c27b63a222b581</gtr:id><gtr:otherNames>Valli I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>ggumeBUhPnZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>977A8A09-09B4-4E6B-9935-B2DFE4D5DB2F</gtr:id><gtr:title>Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b1a2224b337a1dda5d402fdfa5fb51"><gtr:id>49b1a2224b337a1dda5d402fdfa5fb51</gtr:id><gtr:otherNames>Stone JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>U8NDKTscnYE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65F2273F-A51E-4A19-9227-CBCACFB8577F</gtr:id><gtr:title>Thalamic neurochemical abnormalities in individuals with prodromal symptoms of schizophrenia - relationship to auditory event-related potentials.</gtr:title><gtr:parentPublicationTitle>Psychiatry research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b1a2224b337a1dda5d402fdfa5fb51"><gtr:id>49b1a2224b337a1dda5d402fdfa5fb51</gtr:id><gtr:otherNames>Stone JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0165-1781</gtr:issn><gtr:outcomeId>GpRnHbHEwbQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7E6CF45-4C03-4378-9FA3-E1620F2D5EA3</gtr:id><gtr:title>Substance use and regional gray matter volume in individuals at high risk of psychosis.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b1a2224b337a1dda5d402fdfa5fb51"><gtr:id>49b1a2224b337a1dda5d402fdfa5fb51</gtr:id><gtr:otherNames>Stone JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>GbgjTd5vkj2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9424363-A46A-4823-9A73-0EBE083D0F6B</gtr:id><gtr:title>Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b1a2224b337a1dda5d402fdfa5fb51"><gtr:id>49b1a2224b337a1dda5d402fdfa5fb51</gtr:id><gtr:otherNames>Stone JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>9E3AB4B2D59</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E287D651-5E24-417E-BA2E-9CC95DF29202</gtr:id><gtr:title>Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b1a2224b337a1dda5d402fdfa5fb51"><gtr:id>49b1a2224b337a1dda5d402fdfa5fb51</gtr:id><gtr:otherNames>Stone JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>400455B408A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C83141AA-726D-4A9F-9B61-88CD372C0EC1</gtr:id><gtr:title>Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis.</gtr:title><gtr:parentPublicationTitle>Archives of general psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d291d20ff6b7d57155002e6583fb3ce2"><gtr:id>d291d20ff6b7d57155002e6583fb3ce2</gtr:id><gtr:otherNames>Fusar-Poli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-990X</gtr:issn><gtr:outcomeId>T9YhByo5CA9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F021854-F111-41F8-B159-A23487298475</gtr:id><gtr:title>Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study.</gtr:title><gtr:parentPublicationTitle>Archives of general psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7e80c50cd776b047fcf989b44a0ba38"><gtr:id>d7e80c50cd776b047fcf989b44a0ba38</gtr:id><gtr:otherNames>Mechelli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-990X</gtr:issn><gtr:outcomeId>gXCYSN8vbcy</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500477</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>